Skip to main content
. 2019 Dec 19;9(1):e014328. doi: 10.1161/JAHA.119.014328

Figure 1.

Figure 1

Kaplan–Meier estimates of major adverse cardiovascular events (MACEs), the triple end point (cardiovascular death, myocardial infarction [MI], and stroke), and all‐cause mortality by baseline hemoglobin A1c (HbA1c) among patients with diabetes mellitus enrolled in the ACCELERATE (Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes) trial.